Panniculitis with eosinophilic infiltration due to gabexate mesilate (FOY®): Possibility of allergic reaction

Journal of Dermatology

Volumn 24, Issue 4, 1997, Pages 235-242

  Nakayama, Fumiaki ^a,b  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

allergic reaction; eosinophil; eosinophil cationic protein; gabexate mesilate; panniculitis

Indexed keywords

CEFMETAZOLE; DOPAMINE; FAMOTIDINE; GABEXATE MESILATE; UNCLASSIFIED DRUG; WHITE PETROLATUM;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG HYPERSENSITIVITY; EOSINOPHILIA; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PANCREATITIS; PANNICULITIS; SKIN BIOPSY; SKIN TEST;

EID: 0030944002     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1997.tb02780.x     Document Type: Article

References (17)

1. Muramatsu M, Fujii S: Inhibitory effects of ω-guanidino acid esters on trypsin, plasmin, thrombin and plasma kallikrein, J Biorhem, 64: 807-814, 1968.
2. Muramatsu M, Fujii S: Inhibitory effects of ω-guanidino acid esters on trypsin, plasmin, plasma kallikrein and thronibin, Biachim Biophys Aria, 268: 221-224, 1972.
3. Freise J, Schmidt FW, Magerstedt P, Schmid K: Gabexate mesilate and camostate: New inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis, Clin Biorhem, 18: 224-229, 1985.
4. Hirayama S, Uehara S, Itagaki H, Izumiyama S, Sato T: Clinical effects of FOY on pancreatitis, Gendai Iryo, 6: 741-744, 1973. (in Japanese)
5. Kumon K, Yoshiya I, Shimada Y, et al: FOY therapy on disseminated intravascular coagulation (DIC), ICU & CCU, 3: 703-711, 1979. (in Japanese)
6. Taenaka N, Shimada Y, Hirata T, et al: Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis, Critical Care Med, 11: 735-738, 1983.
7. Hattori R, Saegusa Y, Satoh M, et al: Gabexate mesilate (FOY®) induced eosinophilic panniculitis, Nihon Hifu Byori Soshiki Kenkyukai, 4: 12-15, 1988. (in Japanese)
8. Ohara S, Morioka S, Nakakita T: Skin ulcer by gabexate mesilate (FOY®), Rinsyo Derma (Tokyo), 37: 459-461, 1995. (in Japanese)
9. Kumon K, Tanaka K, Kishimoto Y, Saito A, Fujita T: The result of gabexate mesilate (FOY) administration for the treatment of disseminated intravascular coagulation (DIC) seen after open heart surgery, ICU & CCU, 6: 473-479, 1982. (in Japanese)
10. Tai P-C, Spry CJF, Peterson C, Venge P, Olsson I: Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic proteins, Nature, 309: 182-184, 1984.
11. Lever WF, Schaumburg-Lever G: Histopathology of the Skin, 7th ed, JB Lippincott, Philadelphia, 1990, pp 277.
12. Tanno K, Ikarashi K, Sasahara K, Kato M: Incompatibility of cefotiam dihydrochloride in parenteral preparation by high-performance liquid chromatography, Jpn J Antibiotics, 35: 1177-1182, 1982. (in Japanese)
13. Matsuoka Y, Mori T, Yamamoto Y, et al: Toxicities of [ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate (FOY) (II), Ouyou Yakuri, 15: 53-84, 1978. (in Japanese)
14. Rietschel RL, Fowler JF Jr: Fisher's Contact Dermatitis, 4th ed, Williams & Wilkins, Baltimore, 1995, p 30.
15. Young JDE, Peterson C, Venge P, Cohen ZA: Mechanism of membrane damage mediated by human eosinophil cationic protein, Nature, 321: 613-616, 1986.
16. Mikawa K, Akamatsu H, Maekawa N, Nishina N, Obara H, Niwa Y: Inhibitory effect of gabexate mesilate on human neutrophil function, J Int Med Res, 22: 245-254, 1994.
17. Mikawa K, Akamatsu H, Maekawa N, Nishina N, Obara H, Niwa Y: Acceleration of phagocytosis in human neutrophils incubated with gabexate mesilate, J Int Med Res, 22: 292-295, 1994.